Yeah, I think that comes back to the values we had as founders. All of us in different ways, had some impact in our prior endeavors. One of the things that was really important for all of us was to have a real impact on the world and to do things in the right way, even if it was a hard way. From the very beginning, we said we really wanted to do something very innovative around science , we wanted to do real science.
That was one of the conditions for the team to join as well, and very rightly so. But that’s also what Jonathan and I want to do. Rather than start , and that’s six, seven years ago , by launching a product, getting a CGM (Continuous Glucose Monitor), and offering it to the market, we decided to go to the hospital, the actual hospital, St. Thomas Hospital. That’s where the company started , and to first license this amazing research that Tim has been doing on twins for 30 years and build upon it by launching what at that time was called Predict, now it’s called Predict One, which is this start of this ongoing study, this ongoing project to collect the largest amount of data around the microbiome, nutrition, lifestyle, et cetera, in the world, in order to collect the data set that allows us to understand how people respond differently to food, how people are different, how the lifestyles are different, and use a data set together with AI to be able to predict for any individual how any food, any way of eating, any way of eating and living impacts the health real-time.
That’s the reason I went back to the hospital, and I’ll share a funny story that I like to cite to show just how naive we were, particularly myself when we started an endeavor. We said, We’re going to do this study with 1,000 people, 700 of them, twins. Typically the studies were around 20 people because these are real intervention studies. In our case, it was a 14-day intervention study where we collected so much data from the DNA to the microbiome, people were wearing the CGM, and they were eating set meals for a number of days.
We had them in the hospital for a day to take blood through a catheter, through 10 or 11 different time points to measure insulin, to measure the triglycerides rise, and measure the glucose rise , metabolism. It’s a very intense study, typically done only on 20 people, if at all. In this case, we said 1,000. All the scientists thought we were crazy, and probably we were.
The funny story is that we had never done a clinical trial ourselves, ever. We asked the scientists what team we needed to build. They told us , “hey, guys, the first person you need to bring on board is a CRO.” John and I looked at each other and said CRO? Like Chief Revenue Officer? We have zero revenues. It’s only cost. What do you mean? Of course, they were talking about the people who used to be running these clinical trials and what are called CROs (Contract Research Organizations).
To cut a long story short, we interviewed a bunch of people, but we said to ourselves at the end of the interview , we can do better. I think that’s one of the interesting lessons in entrepreneurship or our naivety maybe as entrepreneurs when you approach a problem you don’t know anything about or an industry you know nothing about is that we think about the problem from first principles and by using our experience and approach in building startups, we treat the clinical study of that size as a startup and were able to complete it, I would say, at a fifth or sixth of the time it would have taken other people and probably at a tenth of the cost with many superior results than they would have gotten. This was a fun experience and that was the genesis of the approach.
From the very beginning, we said , “we’re going to do this clinical study, then we’re going to do a similar version of that.” We called it a semi-commercial product. It was a clinical study that was similar to the first one, a bit less intense, but at home here in the US. In that way, we proved that we can do the studies at home and, in effect, do the testing part of our product at home. That’s the evolution of the study and the product that goes from something that’s very intense to something less intense.
Very similar to how Tesla has developed the cars from way more expensive and complicated models to much simpler and less expensive ones.